Recently, Norroy's independent innovative radiation therapy drug 177Lu-NY108(NYM032) injection has been granted clinical trial approval, has been published on the official website of the Drug Evaluation Center of China(CDE).This is Norroy's first approved therapeutic nuclear drug in China and the third clinical approval to date. 177Lu-NY108(NYM032) injection is a small molecule compound with high affinity for prostate specific membrane antigen (PSMA). It is a therapeutic nuclear drug in NY108 pipeline. NY108 is an integrated nuclear drug pipeline in Norroy. Results of a Ph0 clinical study (IIT) showed that, based on Norroy's core technology platform, 177Lu-NY108(NYM032)has a longer retention time in the tumor (t1/2 eff more than 168 hours), faster cyclic clearance, and higher tumor uptake.177Lu-NY108(NYM032) injection is expected to be a new generation of PSMA targeted nuclear drug. Norroy hopes to further improve the safety, effectiveness and economy of prostate cancer nuclide therapy through the integrated combination of the pipeline treatment drugs, in order to better serve the clinical personalized and accurate theranostics of patients.
Next, Norroy will continue to promote the key nodes of the declared and ongoing research projects, actively carry out clinical trial of each pipeline, and strive to bring innovative nuclear drugs to the market as soon as possible to bring more breakthrough theranostics options for patients around the world.